Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allinaire Therapeutics
Belgium's Sequana Sits At Junction Between Pharma And Medtech
The company’s dual drug-device development pipeline is progressing well, especially its direct sodium removal therapy for congestive heart failure.
Chiesi Ready To Reap Benefits Of Rare Disease Expansion
The Italian drugmaker has reported strong sales for 2022 driven by its respiratory drugs but this year will see a more prominent contribution from its rare disease offerings.
Deal Watch: Novo Nordisk Links With Flagship To Create Cardiometabolic, Rare Disease Portfolio
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick
Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.